Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L1TA
|
|||
| Drug Name |
PMID26882240-Compound-1
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
YUNG SHIN PHARM. IND. CO., LTD
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16N2O2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
|
|||
| InChI |
1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
|
|||
| InChIKey |
OQQVFCKUDYMWGV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 170632-47-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:93060
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| Hypoxia-inducible factor 1 (HIF-1) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| Hypoxia-inducible factor 1 (HIF-1) | Target's Patent Info | [1] | ||
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.